Medicaid Drug Rebate Program (MDRP) Summit 2025
IntegriChain is proud to sponsor this year’s Medicaid Drug Rebate Program (MDRP) event, contributing thought leadership on key topics such as IRA rebates and IRA drug price negotiations and best practices around this topic. Our sessions delved into the latest IRA Medicare Part D changes, offering insights and best practices for navigating this evolving landscape and how pharmaceutical manufacturers can prepare for new rebates.
Jeff Baab
Partner, Advisory Services
Session: IRA Implementation at the Crossroads: Strategic Decision Framework for 2026 and Beyond
Date | Time: Tuesday, September 24 | 10:55AM – 11:35 AM
Description: In this session Jeff Baab, Partner, Advisory Services and Kristin Hicks, Partner at Arnold and Porter, will cover topics including:
- Refresh on the Medicare Drug Price Negotiation Program
- Insights from the publication of MFPs from the first round of negotiation
- How may future rounds of negotiation differ?
- What to prepare and best practices on process
- Market access implications of the MFP and changing Part D dynamics
For more on the topics in this presentation, please read our consulting blog post on the IRA.
Jeff Baab
Partner, Advisory Services
Session: IRA Implementation at the Crossroads: Strategic Decision Framework for 2026 and Beyond
Date | Time: Wednesday, September 17 | 8:40 AM – 9:20 AM
Description:In this session Jeff Baab, Partner, Advisory Services and Kristin Hicks, Partner at Arnold and Porter, will cover topics including:
- Examine strategic inflection points as the IRA transitions from initial implementation to mature program operations, including essential recalibrations for commercial planning, forecasting, and portfolio optimization.
- Analyze emerging patterns in market response across different stakeholder groups, illuminating how successful organizations are adapting their decision frameworks beyond basic compliance
- Explore the evolution of data-driven approaches for navigating negotiation preparation, financial modeling, and commercial contracting in response to early program experiences
- Develop forward-looking strategies that balance short-term tactical needs with long-term portfolio considerations as the program expands to include Part B drugs and additional therapeutic categories